One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Immunotherapy: balancing the risks and benefits
doi : 10.1016/S1470-2045(24)00028-7
Volume 25, Issue 2, February 2024, Page 147
Targeted alpha therapy: a new tool for advanced prostate cancer
Kalevi Kairemo
doi : 10.1016/S1470-2045(23)00672-1
Volume 25, Issue 2, February 2024, Pages 148-149
Developing therapies for triple-negative breast cancer subtypes
*Alicia Okines, Nicholas Turner
doi : 10.1016/S1470-2045(23)00639-3
Volume 25, Issue 2, February 2024, Pages 149-151
Multiplex immunofluorescence for tumour immune biomarker discovery
Juha P V?yrynen
doi : 10.1016/S1470-2045(23)00583-1
Volume 25, Issue 2, February 2024, Pages 151-152
Modelling radiotherapy availability in the Asia-Pacific region
Yolande Lievens
doi : 10.1016/S1470-2045(23)00655-1
Volume 25, Issue 2, February 2024, Pages 152-154
Secondary prevention of anthracycline cardiotoxicity in childhood cancer survivors
*Jan M Leerink, Elizabeth A M Feijen
doi : 10.1016/S1470-2045(24)00001-9
Volume 25, Issue 2, February 2024, Pages 154-156
Accelerating neoadjuvant chemotherapy for muscle-invasive bladder cancer
*Laura S Mertens, Michiel S van der Heijden
doi : 10.1016/S1470-2045(23)00626-5
Volume 25, Issue 2, February 2024, Pages 156-157
Accelerating progress on EU cancer control
Andreas Charalambous, Richard Price, Prabhat Jha
doi : 10.1016/S1470-2045(24)00002-0
Volume 25, Issue 2, February 2024, Pages 158-160
Expression of concern—Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study
Thank you to The Lancet Oncology's reviewers in 2023
doi : 10.1016/S1470-2045(24)00007-X
Volume 25, Issue 2, February 2024, Pages e43-e49
Pembrolizumab plus chemotherapy for advanced gastric cancer
Chen-yu Huang, *Xiao-bing Wu
doi : 10.1016/S1470-2045(23)00573-9
Volume 25, Issue 2, February 2024, Page e50
Pembrolizumab plus chemotherapy for advanced gastric cancer
Tim Schutte, Sarah Derks, Hanneke W M van Laarhoven
doi : 10.1016/S1470-2045(23)00621-6
Volume 25, Issue 2, February 2024, Page e51
Pembrolizumab plus chemotherapy for advanced gastric cancer – Authors' reply
*Sun Young Rha, Sonal Bordia
doi : 10.1016/S1470-2045(24)00022-6
Volume 25, Issue 2, February 2024, Page e52
Classifying and grading liposarcoma by CT
*Tomomi Sanomachi, Hiroto Ishiki
doi : 10.1016/S1470-2045(24)00005-6
Volume 25, Issue 2, February 2024, Page e53
The GLOW trial in chronic lymphocytic leukaemia
Martin Fey
doi : 10.1016/S1470-2045(23)00620-4
Volume 25, Issue 2, February 2024, Page e54
The GLOW trial in chronic lymphocytic leukaemia
Michel van Gelder, Mels Hoogendoorn, Doreen te Raa
doi : 10.1016/S1470-2045(23)00677-0
Volume 25, Issue 2, February 2024, Page e55
The GLOW trial in chronic lymphocytic leukaemia – Authors' reply
*Carsten U Niemann, Arnon P Kater
doi : 10.1016/S1470-2045(24)00024-X
Volume 25, Issue 2, February 2024, Page e56
Primary ovarian insufficiency prediction in adult survivors of childhood cancer: model concerns
William Hamish B Wallace, Tom W Kelsey
doi : 10.1016/S1470-2045(23)00643-5
Volume 25, Issue 2, February 2024, Page e57
Primary ovarian insufficiency prediction in adult survivors of childhood cancer: model concerns
Fangjieyi Zheng, Kening Chen, *Wenquan Niu
doi : 10.1016/S1470-2045(23)00650-2
Volume 25, Issue 2, February 2024, Page e58
Primary ovarian insufficiency prediction in adult survivors of childhood cancer: model concerns – Authors' reply
Cindy Im, Zhe Lu, Yutaka Yasui, Melissa M Hudson, Kirsten K Ness, Gregory T Armstrong, Sogol Mostoufi-Moab, *Yan Yuan
doi : 10.1016/S1470-2045(24)00027-5
Volume 25, Issue 2, February 2024, Pages e59-e60
Correction to Lancet Oncol 2020; 21: 796–807
doi : 10.1016/S1470-2045(24)00013-5
Volume 25, Issue 2, February 2024, Page e61
Correction to Lancet Oncol 2023; 24: 1018–28
doi : 10.1016/S1470-2045(24)00019-6
Volume 25, Issue 2, February 2024, Page e61
2023 ASH annual meeting
Emma Cookson
doi : 10.1016/S1470-2045(23)00654-X
Volume 25, Issue 2, February 2024, Page 161
High health expenses in the WHO Western Pacific region
Manjulika Das
doi : 10.1016/S1470-2045(23)00652-6
Volume 25, Issue 2, February 2024, Page 162
Sub-Saharan Africa's harmonised cancer guidelines
Munyaradzi Makoni
doi : 10.1016/S1470-2045(23)00653-8
Volume 25, Issue 2, February 2024, Page 163
Nigerian competition watchdog fines British American Tobacco
Talha Burki
doi : 10.1016/S1470-2045(24)00003-2
Volume 25, Issue 2, February 2024, Page 164
Cancer misinformation puts patients in harm's way
Bryant Furlow
doi : 10.1016/S1470-2045(24)00011-1
Volume 25, Issue 2, February 2024, Pages 165-166
US radiation oncology organisations work towards Medicare payment reform
Manjulika Das
doi : 10.1016/S1470-2045(24)00029-9
Volume 25, Issue 2, February 2024, Page e62
Treatment of metastatic pancreatic cancer: 25 years of innovation with little progress for patients
*Bishal Gyawali, Christopher M Booth
doi : 10.1016/S1470-2045(23)00516-8
Volume 25, Issue 2, February 2024, Pages 167-170
World Oncology Forum amplifies its appeal in global fight against cancer
Franco Cavalli, Bente Mikkelsen, Elisabete Weiderpass, Richard Sullivan, David Jaffray, Mary Gospodarowicz
doi : 10.1016/S1470-2045(24)00010-X
Volume 25, Issue 2, February 2024, Pages 170-174
Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre, retrospective study
Mike M Sathekge, Ismaheel O Lawal, Chandrasekhar Bal, Frank Bruchertseifer, Sajana Ballal, Giuseppe Cardaci, Cindy Davis, Mathias Eiber, Türkay Hekimsoy, Otto Knoesen, Clemens Kratochwil, Nat P Lenzo, Johncy Mahapane, Letjie C Maserumule, Amanda H Mdlophane, Kgomotso M G Mokoala, Honest Ndlovu, Vineet Pant, Hendrik Rathke, Janet Reed, Ishita B Sen, Aviral Singh, Ashwani Sood, Robert Tauber, Parul Thakral, Madhav Prasad Yadav, Alfred Morgenstern
doi : 10.1016/S1470-2045(23)00638-1
Volume 25, Issue 2, February 2024, Pages 175-183
Optimising first-line subtyping-based therapy in triple-negative breast cancer (FUTURE-SUPER): a multi-cohort, randomised, phase 2 trial
Lei Fan*, Zhong-Hua Wang*, Lin-Xiaoxi Ma*, Song-Yang Wu*, Jiong Wu*, Ke-Da Yu*, Xin-Yi Sui, Ying Xu, Xi-Yu Liu, Li Chen, Wen-Juan Zhang, Xi Jin, Qin Xiao, Ruo-Hong Shui, Yi Xiao, Han Wang, Yun-Song Yang, Xiao-Yan Huang, A-Yong Cao, Jun-Jie Li, Gen-Hong Di, Guang-Yu Liu, Wen-Tao Yang, Xin Hu, Yan Xia, Qian-Nan Liang, Yi-Zhou Jiang†, Zhi-Ming Shaoâ€
doi : 10.1016/S1470-2045(23)00579-X
Volume 25, Issue 2, February 2024, Pages 184-197
Multiplex analysis of intratumoural immune infiltrate and prognosis in patients with stage II–III colorectal cancer from the SCOT and QUASAR 2 trials: a retrospective analysis
Anja L Frei, Anthony McGuigan, Ritik R A K Sinha, Faiz Jabbar, Luciana Gneo, Tijana Tomasevic, Andrea Harkin, Tim Iveson, Mark P Saunders, Karin A Oien, Noori Maka, Francesco Pezzella, Leticia Campo, Molly Browne, Mark Glaire, Wanja Kildal, Havard E Danielsen, Jennifer Hay, Joanne Edwards, Owen Sansom, Caroline Kelly, Ian Tomlinson, Rachel Kerr, David Kerr, Enric Domingo, TransSCOT consortium*, David N Church†, Viktor H Koelzer
doi : 10.1016/S1470-2045(23)00560-0
Volume 25, Issue 2, February 2024, Pages 198-211
Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study
Kohei Shitara, Sun Young Rha, Lucjan S Wyrwicz, Takashi Oshima, Nina Karaseva, Mikhail Osipov, Hisateru Yasui, Hiroshi Yabusaki, Sergey Afanasyev, Young-Kyu Park, Salah-Eddin Al-Batran, Takaki Yoshikawa, Patricio Yanez, Maria Di Bartolomeo, Sara Lonardi, Josep Tabernero, Eric Van Cutsem, Yelena Y Janjigian, Do-Youn Oh, Jianming Xu, Xiao Fang, Chie-Schin Shih, Pooja Bhagia, Yung-Jue Bang, on behalf of the KEYNOTE-585 investigators
doi : 10.1016/S1470-2045(23)00541-7
Volume 25, Issue 2, February 2024, Pages 212-224
Current and projected gaps in the availability of radiotherapy in the Asia-Pacific region: a country income-group analysis
doi : 10.1016/S1470-2045(23)00619-8
Volume 25, Issue 2, February 2024, Pages 225-234
Effect of carvedilol versus placebo on cardiac function in anthracycline-exposed survivors of childhood cancer (PREVENT-HF): a randomised, controlled, phase 2b trial
Saro H Armenian, Melissa M Hudson, Lanie Lindenfeld, Sitong Chen, Eric J Chow, Steven Colan, Willem Collier, Xiaohong Su, Edward Marcus, Meagan Echevarria, Aleksi Iukuridze, Leslie L Robison, F Lennie Wong, Ming Hui Chen*, Smita Bhatia
doi : 10.1016/S1470-2045(23)00637-X
Volume 25, Issue 2, February 2024, Pages 235-245
Low-dose versus standard-dose olanzapine with triple antiemetic therapy for prevention of highly emetogenic chemotherapy-induced nausea and vomiting in patients with solid tumours: a single-centre, open-label, non-inferiority, randomised, controlled, phase 3 trial
Jyoti Bajpai, Venkatesh Kapu, Sushmita Rath, Sravan Kumar, Anbarasan Sekar, Priyanka Patil, Altaf Siddiqui, Srikanth Anne, Akash Pawar, Sujay Srinivas, Prabhat Bhargava, Seema Gulia, Vanita Noronha, Amit Joshi, Kumar Prabhash, Shripad Banavali, Rajiv Sarin, Rajendra Badwe, Sudeep Gupta
doi : 10.1016/S1470-2045(23)00628-9
Volume 25, Issue 2, February 2024, Pages 246-254
Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study
Christian Pfister, Gwenaelle Gravis, Aude Flechon, Christine Chevreau, Hakim Mahammedi, Brigitte Laguerre, Aline Guillot, Florence Joly, Michel Soulie, Yves Allory, Valentin Harter, Stéphane Culine, for the VESPER Trial Investigators
doi : 10.1016/S1470-2045(23)00587-9
Volume 25, Issue 2, February 2024, Pages 255-264
Quality indicators for evaluating cancer care in low-income and middle-income country settings: a multinational modified Delphi study
Megan McLeod, Julie Torode, Kari Leung, Nirmala Bhoo-Pathy, Christopher Booth, Jade Chakowa, Julie Gralow, Andre Ilbawi, Jacek Jassem, Jeannette Parkes, Merixtell Mallafré-Larrosa, Miriam Mutebi, CS Pramesh, Manju Sengar, Audrey Tsunoda, Karla Unger-Salda?a, Verna Vanderpuye, Aasim Yusuf, Richard Sullivan*, Ajay Aggarwal
doi : 10.1016/S1470-2045(23)00568-5
Volume 25, Issue 2, February 2024, Pages e63-e72
International multidisciplinary consensus on the integration of radiotherapy with new systemic treatments for breast cancer: European Society for Radiotherapy and Oncology (ESTRO)-endorsed recommendations
Icro Meattini, Carlotta Becherini, Saverio Caini, Charlotte E Coles, Javier Cortes, Giuseppe Curigliano, Evandro de Azambuja, Clare M Isacke, Nadia Harbeck, Orit Kaidar-Person, Elisabetta Marangoni, Birgitte V Offersen, Hope S Rugo, Viola Salvestrini, Luca Visani, Andrea Morandi, Matteo Lambertini, Philip Poortmans*, Lorenzo Livi*, on behalf of the Consensus Panellist Group
doi : 10.1016/S1470-2045(23)00534-X
Volume 25, Issue 2, February 2024, Pages e73-e83
Cancer care and treatment during homelessness
Ramin Asgary
doi : 10.1016/S1470-2045(23)00567-3
Volume 25, Issue 2, February 2024, Pages e84-e90
Cutaneous blisters mimicking bullous pemphigoid
Yue-Qian Yu, Jing Wen, Xue-Chao Chen, Hong Liu, Fu-Ren Zhang
doi : 10.1016/S1470-2045(23)00647-2
Volume 25, Issue 2, February 2024, Page e91
